Landscapes / Targets
complement
30 drugs act on complement, in 83 active trials · Any stage · updated 18 Nov 2026
FollowEvery change as it happens, and a Monday email
Drugs30
| Drug | How it works | Company | Stage
Sources: FDA: the drug development process, ClinicalTrials.gov glossary | Next date
| Details |
|---|---|---|---|---|---|
Complement inhibitor |
Approved | 7 Dec 2026soonPhase 3 trial completes | |||
| How it works | Blocks part of the complement system | ||||
| Next date | 7 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | NMOSD, Neuromyelitis Optica Spectrum Disorders | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved | 15 Dec 2026soonPhase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 15 Dec 2026 · Phase 3 trial completes | ||||
| Also tested for | Generalized Myasthenia Gravis, gMG | ||||
| Open drug page | |||||
Complement factor B inhibitor |
Novartis · Public NVS |
Approved | 30 Dec 2026Phase 2 trial completes | ||
| Next date | 30 Dec 2026 · Phase 2 trial completes | ||||
| Also tested for | Atypical Hemolytic Uremic Syndrome, C3 Glomerulopathy and 11 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Roche · Public ROG.SW |
Approved | 18 Apr 2027Phase 3 trial completes | ||
| How it works | An antibody | ||||
| Next date | 18 Apr 2027 · Phase 3 trial completes | ||||
| Also tested for | Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome | ||||
| Open drug page | |||||
Complement inhibitor |
Approved | 12 May 2027Phase 2/3 trial completes | |||
| How it works | Blocks part of the complement system | ||||
| Next date | 12 May 2027 · Phase 2/3 trial completes | ||||
| Also tested for | Generalized Myasthenia Gravis | ||||
| Open drug page | |||||
Complement factor D inhibitor |
Approved | 28 May 2027Phase 3 trial completes | |||
| Next date | 28 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Paroxysmal Nocturnal Hemoglobinuria, PNH and 1 more | ||||
| Open drug page | |||||
Complement inhibitor |
Approved | 25 Jun 2027Phase 4 trial completes | |||
| How it works | Blocks part of the complement system | ||||
| Next date | 25 Jun 2027 · Phase 4 trial completes | ||||
| Also tested for | Generalized Myasthenia Gravis, gMG and 13 more | ||||
| Open drug page | |||||
Complement inhibitor |
Approved | 30 Jun 2027Phase 4 trial completes | |||
| How it works | Blocks part of the complement system | ||||
| Next date | 30 Jun 2027 · Phase 4 trial completes | ||||
| Also tested for | Geographic Atrophy, Age-Related Macular Degeneration | ||||
| Open drug page | |||||
Complement inhibitor |
Approved | Jul 2027Phase 3 trial completes | |||
| How it works | Blocks part of the complement system | ||||
| Next date | Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN), Paroxysmal Nocturnal Hemoglobinuria (PNH) and 13 more | ||||
| Open drug page | |||||
Complement inhibitor |
Regeneron · Public REGN |
Approved | 31 Jul 2028Phase 3 trial completes | ||
| How it works | Blocks part of the complement system | ||||
| Next date | 31 Jul 2028 · Phase 3 trial completes | ||||
| Also tested for | Paroxysmal Nocturnal Hemoglobinuria, Geographic Atrophy (GA) and 3 more | ||||
| Open drug page | |||||
Monoclonal antibody |
Approved in the EU | Jul 2028Phase 2 trial completes | |||
| How it works | An antibody | ||||
| Next date | Jul 2028 · Phase 2 trial completes | ||||
| Also tested for | Acute Respiratory Distress Syndrome (ARDS), ARDS and 2 more | ||||
| Open drug page | |||||
— |
Phase 3 | Nov 2026soonPhase 3 trial completes | |||
| Next date | Nov 2026 · Phase 3 trial completes | ||||
| Also tested for | Paroxysmal Nocturnal Hemoglobinuria, Primary IgA Nephropathy | ||||
| Open drug page | |||||
— |
Phase 2/3 | Dec 2026Phase 2/3 trial completes | |||
| Next date | Dec 2026 · Phase 2/3 trial completes | ||||
| Also tested for | Hypoxic-Ischemic Encephalopathy, Acute Exacerbation of Chronic Obstructive Pulmonary Disease and 1 more | ||||
| Open drug page | |||||
Artificial immunoglobulin |
Phase 3 | 31 May 2027Phase 3 trial completes | |||
| How it works | An antibody | ||||
| Next date | 31 May 2027 · Phase 3 trial completes | ||||
| Also tested for | Guillain-Barre Syndrome | ||||
| Open drug page | |||||
— |
Phase 3 | 31 Jul 2027Phase 3 trial completes | |||
| Next date | 31 Jul 2027 · Phase 3 trial completes | ||||
| Also tested for | Geographic Atrophy | ||||
| Open drug page | |||||
— |
Phase 3 | 30 Sep 2027Phase 3 trial completes | |||
| Next date | 30 Sep 2027 · Phase 3 trial completes | ||||
| Also tested for | Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Nocturnal Hemoglobinuria, PNH | ||||
| Open drug page | |||||
— |
Roche · Public ROG.SW |
Phase 3 | 25 May 2028Phase 3 trial completes | ||
| Next date | 25 May 2028 · Phase 3 trial completes | ||||
| Also tested for | Primary IgA Nephropathy | ||||
| Open drug page | |||||
Small interfering RNA |
Regeneron · Public REGN |
Phase 3 | 31 Jul 2028Phase 3 trial completes | ||
| How it works | A short strand of RNA that switches off one gene | ||||
| Next date | 31 Jul 2028 · Phase 3 trial completes | ||||
| Also tested for | Paroxysmal Nocturnal Hemoglobinuria, Generalized Myasthenia Gravis and 2 more | ||||
| Open drug page | |||||
— |
Phase 2/3 | 1 Feb 2029Phase 2/3 trial completes | |||
| Next date | 1 Feb 2029 · Phase 2/3 trial completes | ||||
| Also tested for | Adults With Neovascular Age-related Macular Degeneration | ||||
| Open drug page | |||||
— |
Phase 2 | 30 Dec 2027Phase 2 trial completes | |||
| Next date | 30 Dec 2027 · Phase 2 trial completes | ||||
| Also tested for | PNH - Paroxysmal Nocturnal Hemoglobinuria, Paroxysmal Nocturnal Hemoglobinuria and 1 more | ||||
| Open drug page | |||||
No drugs match “”.
About this list
- Checked
- 30 of 30 drugs. How we check
- Matches
- The mechanism of checked drugs, and drug names, so a drug not checked yet may be missing.
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · openFDA updated 17 Nov 2026